Completed
Despite the worldwide effort to develop safe and effective vaccines against COVID-19 and ramp up production capacity, it is inevitable that initial vaccine supply will be limited. Therefore, policymakers must develop plans to ensure the equitable allocation of limited doses until there is sufficient global supply.
In response to a request from the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC), the National Academies have formed a committee that will produce a consensus study to assist policymakers in the U.S. and global health communities in planning for equitable allocation of vaccines against COVID-19.
Featured publication
Consensus
ยท2020
In response to the coronavirus disease 2019 (COVID-19) pandemic and the societal disruption it has brought, national governments and the international community have invested billions of dollars and immense amounts of human resources to develop a safe and effective vaccine in an unprecedented time f...
View details
Description
An ad hoc committee of the National Academies of Sciences, Engineering, and Medicine will develop an overarching framework for vaccine allocation to assist policymakers in the domestic and global health communities in planning for equitable allocation of vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The expectation is that such a framework would inform the decisions by health authorities, including the Advisory Committee on Immunization Practices (ACIP), as they create and implement national and/or local guidelines for SARS-CoV-2 vaccine allocation. As part of this effort, the committee will consider the following:
- What criteria should be used in setting priorities for equitable allocation of vaccine?
- How should the criteria be applied in determining the first tier of vaccine recipients? As more vaccine becomes available, what populations should be added successively to the priority list of recipients? How do we take into account factors such as:
- Health disparities and other health access issues
- Individuals at higher risk (e.g., elderly, underlying health conditions)
- Occupations at higher risk (e.g., health care workers, essential industries, meat packing plants, military)
- Populations at higher risk (e.g., racial and ethnic groups, incarcerated individuals, residents of nursing homes, individuals who are homeless)
- Geographic distribution of active virus spread
- Countries/populations involved in clinical trials
- How will the framework apply in various scenarios (e.g., different characteristics of vaccines and differing available doses)?
- If multiple vaccine candidates are available, how should we ensure equity?
- How can countries ensure equity in allocation of COVID-19 vaccines?
- For the US, how can communities of color be assured access to vaccination?
- How can we communicate to the American public about vaccine allocation to minimize perceptions of lack of equity?
- What steps should be taken to mitigate vaccine hesitancy, especially among high-priority populations?
As part of the overall study, the committee will produce a discussion draft of the framework for public comment, and hold a public workshop to solicit feedback from external stakeholders.
Collaborators
Committee
Co-Chair
Co-Chair
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Committee Membership Roster Comments
Note: There was a change in the committee membership with the appointment of Dr. Michael Wassermen effective 07/30/20.
Sponsors
Centers for Disease Control and Prevention
National Institutes of Health
Staff
Lisa Brown
Lead
Emma Fine
Rebecca Chevat
Elizabeth Finkelman
Benjamin Kahn
Aurelia Attal-Juncqua
Major units and sub-units
Center for Health, People, and Places
Lead
National Academy of Medicine
Lead
Health and Medicine Division
Lead
Division of Behavioral and Social Sciences and Education
Lead
Board on Population Health and Public Health Practice
Lead
Board on Health Sciences Policy
Lead
Health Care and Public Health Program Area
Lead
Biomedical and Health Sciences Program Area
Lead